Aphaia’s oral prediabetes therapy hits main goal in mid-stage study

Aphaia Pharma announced Thursday that its investigational oral glucose formulation, called APHD-012, met the primary endpoint of a Phase II study to treat prediabetes. The results come ahead of expected data in obesity and associated metabolic diseases.